Table 4. Tumour control rates according to serum levels of IL-6 and IL-1β in patients with gemcitabine monotherapy for advanced pancreatic cancer.

IL-6/IL-1β classification	N	Median (95% CI) (%)	P-value
IL-6Low/IL-1βLow	25	76.0 (56.6–88.5)	Ref.
IL-6Low/IL-1βHigh	5	60.0 (23.1–88.2)	0.589
IL-6High/IL-1βLow	15	40.0 (19.8–64.3)	0.042
IL-6High/IL-1βHigh	15	20.0 (7.0–45.2)	<0.001

Abbreviations: CI=confidence interval; IL=interleukin.